Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. METHODS: In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we randomly assigned 1012 and 1040 patients, respectively, with mild-to-moderate Alzheimer's disease to receive placebo or solanezumab (administered intravenously at a dose of 400 mg) every 4 weeks for 18 months. The primary outcomes were the changes from baseline to week 80 in scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11; range, 0 to 70, with higher scores indicating greater cognitive impairment) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL; range, 0 to 78, with lower scores indicating worse functioning). After analysis of data from EXPEDITION 1, the primary outcome for EXPEDITION 2 was revised to the change in scores on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; range, 0 to 90, with higher scores indicating greater impairment), in patients with mild Alzheimer's disease. RESULTS: Neither study showed significant improvement in the primary outcomes. The modeled difference between groups (solanezumab group minus placebo group) in the change from baseline was -0.8 points for the ADAS-cog11 score (95% confidence interval [CI], -2.1 to 0.5; P=0.24) and -0.4 points for the ADCS-ADL score (95% CI, -2.3 to 1.4; P=0.64) in EXPEDITION 1 and -1.3 points (95% CI, -2.5 to 0.3; P=0.06) and 1.6 points (95% CI, -0.2 to 3.3; P=0.08), respectively, in EXPEDITION 2. Between-group differences in the changes in the ADAS-cog14 score were -1.7 points in patients with mild Alzheimer's disease (95% CI, -3.5 to 0.1; P=0.06) and -1.5 in patients with moderate Alzheimer's disease (95% CI, -4.1 to 1.1; P=0.26). In the combined safety data set, the incidence of amyloid-related imaging abnormalities with edema or hemorrhage was 0.9% with solanezumab and 0.4% with placebo for edema (P=0.27) and 4.9% and 5.6%, respectively, for hemorrhage (P=0.49). CONCLUSIONS: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [45]
In the citing paper
“bapineuzumab and solanezumab showed no cognitive improvement in Phase 3 trials [46,47]”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“Clinical trials often fail to deliver benefits.”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [57]
In the citing paper
“While recent clinical trials of anti‐amyloid therapies, such as donanemab and lecanemab, 2 , 3 have shown promising results, the failures of earlier treatments like solanezumab and bapineuzumab indicate that targeting a single AD‐specific pathological process is insufficient to mitigate cognitive decline. 4 , 5 , 6”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [6]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Assessing Quality of Life in Older Adults With Cognitive Impairment
Logsdon, R. G., Gibbons, L. E., McCurry, S. M., & Teri, L. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200205000-00016 · Cited by 1,381
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Self-citationAn Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Research works printed but not linked: 2
- Wimo A, Wetterholm AL, Mastey V, Winbald B. Evaluations of resource utilization and caregiver time in anti-dementia drug trials- a quantitative battery. In: Wimo A, Jonsson B, Karlsson G, Winbald B, eds. The health economics of dementia. London: John Wiley, 1998:465-99.
- Kind P. 1996. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 401–500 of 1,006
Carbonell, F., Iturria‐Medina, Y., & Evans, A. C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00037 · Cited by 74
“Their results provided an efficient ranking of multiple AD interventions, which might explain why recent single-target Aβ-based therapies failed to improve clinical outcomes in AD (118, 119).”
ResultRaikwar, S. P., Thangavel, R., Dubova, I., Selvakumar, G. P., Ahmed, M. E., Kempuraj, D., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1068-y · Cited by 73
Collij, L. E., Konijnenberg, E., Reimand, J., ten Kate, M., den Braber, A., Alves, I. L., Zwan, M. D., Yaqub, M. M., van Assema, D. M. E., Wink, A. M., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.211532 · Cited by 66
“Our results may have consequences for drug-intervention studies focused on early populations, since using the visual assessment of SUVr images as an inclusion criterion could result in false-positive inclusion due to the observed overestimation of cortical amyloid burden (32,33).”
Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system
Quitterer, U., & AbdAlla, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.04.014 · Cited by 77
Gene expression parallels synaptic excitability and plasticity changes in Alzheimer’s disease
Saura, C. A., Parra-Damas, A., & Enriquez-Barreto, L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00318 · Cited by 65
Agadjanyan, M. G., Petrovsky, N., & Ghochikyan, A. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1884 · Cited by 64
Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy
Landen, J. W., Cohen, S., Billing, C. B., Cronenberger, C., Styren, S., Burstein, A. H., Sattler, C., Lee, J., Jack, C. R., Kantarci, K., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.04.003 · Cited by 64
“The results of this study are broadly consistent with those of the phase-III bapineuzumab and solanezumab studies in similar patient populations, which failed to meet their primary end points [4,5].”
BackgroundResultBohm, C., Chen, F., Sevalle, J., Qamar, S., Dodd, R., Li, Y., Schmitt-Ulms, G., Fraser, P. E., & St George-Hyslop, P. H. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.02.016 · Cited by 63
Koch, G., Motta, C., Bonnì, S., Pellicciari, M. C., Picazio, S., Casula, E. P., Maiella, M., Lorenzo, F. D., Ponzo, V., Ferrari, C., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.10372 · Cited by 65
Deng, Z., Jiang, J., Wang, J., Pan, D., Zhu, Y., Li, H., Zhang, X., Liu, X., Xu, Y., Li, Y., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19378 · Cited by 75
Amyloid-beta immunotherapy: the hope for Alzheimer disease?
Barrera-Ocampo, A., & Lopera, F. (2016) · Colombia Medica · doi:10.25100/cm.v47i4.2640 · Cited by 63
Giacomelli, C., Daniele, S., & Martini, C. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.01.017 · Cited by 79
Ahsan, A. U., Sharma, V. L., Wani, A., & Chopra, M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01969-4 · Cited by 71
Imaging endpoints for clinical trials in Alzheimer’s disease
Cash, D. M., Rohrer, J. D., Ryan, N. S., Ourselin, S., & Fox, N. C. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0087-9 · Cited by 62
Mallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.005 · Cited by 69
Zhang, T., Wei, K., Zhou, X., Qian, Y., Feng, S., Wang, R., Cui, G., Tao, R., Guo, W., Duan, Y., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.10.012 · Cited by 63
“However, several promising drugs targeting Ab or tau failed to rescue the cognitive deficits of AD patients or delay the progression of the disease in recent clinical trials (Cacabelos, 2018; Doody et al., 2014).”
BackgroundQu, L., Li, S., Ji, L., Luo, S., Ding, M., Yin, F., Wang, C., Luo, H., Lu, D., Liu, X., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113889 · Cited by 61
Immunotherapies for Alzheimer’s Disease—A Review
Valiukas, Z., Ephraim, R., Tangalakis, K., Davidson, M., Apostolopoulos, V., & Feehan, J. (2022) · Vaccines · doi:10.3390/vaccines10091527 · Cited by 81
“Thirteen phase III trials using the mAbs bapineuzumab [70], solanezumab [71], gantenerumab [72,73], and crenezumab [74] have been conducted in recent years, however, all were discontinued due to a lack of efficacy on improving cognitive function (Table 1).”
BackgroundAlkhalifa, A. E., Mokhlf, A. A., Ali, H., Al-Ghraiybah, N. F., & Syropoulou, V. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15090437 · Cited by 77
“%) in the combined Phase 3 EXPEDITION trials that included over 2000 participants [121].”
The Role of Mitochondrial Dysfunction in the Progression of Alzheimer’s Disease
Desler, C., Lillenes, M. S., Tønjum, T., & Rasmussen, L. J. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170616110111 · Cited by 61
Fiorito, J., Vendôme, J., Saeed, F., Staniszewski, A., Zhang, H., Yan, S., Deng, S., Arancio, O., & Landry, D. W. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00979 · Cited by 60
Kochman, U., Sitka, H., Kuźniar, J., Czaja, M., Kozubek, P., Beszłej, J. A., & Leszek, J. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05417-z · Cited by 60
Alzheimer’s Disease – The Past, the Present and the Future
Botchway, B. O. A., & Iyer, I. C. (2017) · Science Journal of Clinical Medicine · doi:10.11648/j.sjcm.20170601.11 · Cited by 63
Current and emerging brain applications of MR-guided focused ultrasound
Meng, Y., Suppiah, S., Mithani, K., Solomon, B., Schwartz, M. L., & Lipsman, N. (2017) · Journal of Therapeutic Ultrasound · doi:10.1186/s40349-017-0105-z · Cited by 66
“While they have proven to be effective both histologically and behaviorally in animal models and early clinical trials, there has yet to be an immunotherapy proven to be clinically effective in phase 3 clinical trials [81, 82].”
BackgroundLandlinger, C., Oberleitner, L., Gruber, P., Noiges, B., Yatsyk, K., Santic, R., Mandler, M., & Staffler, G. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0369-6 · Cited by 68
Khan, T. K., & Alkon, D. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150238 · Cited by 67
Antibody Approaches To Treat Brain Diseases
Neves, V., Aires-da-Silva, F., Côrte-Real, S., & Castanho, M. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.10.005 · Cited by 56
The Molecular and Neuropathological Consequences of Genetic Risk for Alzheimer's Dementia
Tasaki, S., Gaiteri, C., Mostafavi, S., De Jager, P. L., & Bennett, D. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00699 · Cited by 59
“…al., 2016; Bennett, 2017), inadequacy of animal models based on these variants (Sabbagh et al., 2013; Burns et al., 2015; Foley et al., 2015), or external factors, such as economics of trial failures in Alzheimer’s dementia (Doody et al., 2013, 2014; Cummings et al., 2014; Salloway et al., 2014).”
BackgroundThe Future of Anti-Amyloid Trials
Aisen, P. S., Cummings, J., Doody, R., Kramer, L., Salloway, S., Selkoe, D. J., Sims, J., Sperling, R. A., & Vellas, B. (2020) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2020.24 · Cited by 59
Self-citationPan, X., Chen, Z., Fei, G., Pan, S., Bao, W., Ren, S., Guan, Y., & Zhong, C. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0067-0 · Cited by 59
Zhou, Y., Wang, Z., Li, W., Hong, H., Chen, J., Tian, Y., & Liu, Z. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26700 · Cited by 59
RetractedKumar, N. N., Pizzo, M. E., Nehra, G., Wilken-Resman, B., Boroumand, S., & Thorne, R. G. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00548 · Cited by 69
Abate, G., Frisoni, G. B., Bourdon, J., Piccirella, S., Memo, M., & Uberti, D. L. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00732-0 · Cited by 62
Risk factors for subjective cognitive decline: the CABLE study
Chen, W., Hu, H., Ou, Y., Bi, Y., Ma, Y., Tan, L., & Yu, J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01711-1 · Cited by 63
“The failure of several previous clinical trials of therapies in the dementia or mild cognitive impairment (MCI) stages further encouraged researchers to shift their focus to the preclinical stage of AD [2, 3].”
ResultMacfarlane, S., Grimmer, T., Teo, K. G., O'Brien, T. J., Woodward, M., Grunfeld, J. A., Mander, A. G., Brodtmann, A. G., Brew, B. J., Morris, P., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100016 · Cited by 78
“The overall mixed success of amyloid-targeting treatments [8– 11] and their potential for severe adverse events (AEs) [12,13] has high-lighted the need for safer effective treatments.”
Developing therapeutic vaccines against Alzheimer’s disease
Wisniewski, T., & Drummond, E. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1121815 · Cited by 59
Beta-Amyloid and Tau-Protein: Structure, Interaction, and Prion-Like Properties
Tatarnikova, O. G., Орлов, М. А., & Bobkova, N. V. (2015) · Biochemistry (Moscow) · doi:10.1134/s000629791513012x · Cited by 72
Delnomdedieu, M., Duvvuri, S., Li, D. J., Atassi, N., Lu, M., Brashear, H. R., Liu, E., Ness, S., & Kupiec, J. W. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0177-y · Cited by 59
Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
Panza, F., Seripa, D., Solfrizzi, V., Imbimbo, B. P., Lozupone, M., Leo, A., Sardone, R., Gagliardi, G., Lofano, L., Creanza, B. C., et al. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1241232 · Cited by 59
“Unfortunately, all these trials did not match their primary efficacy end points, althoughboth provided precious information on AD diagnostic accuracy and biomarkers [82,83], and a subgroup analysis of pooled data of Phase III solanezumab trials showed a statistically significant 34% reduction in cognitive decline in p…”
BackgroundMethodResultInfluentialThomas, M. H., Pelleïeux, S., Vitale, N., & Olivier, J. L. (2016) · Biochimie · doi:10.1016/j.biochi.2016.07.013 · Cited by 62
Scuteri, D., Morrone, L. A., Rombolà, L., Avato, P., Bilia, A. R., Corasaniti, M. T., Sakurada, S., Sakurada, T., & Bagetta, G. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/9416305 · Cited by 73
Cai, X., Zhang, K., Xie, X., Zhu, X., Feng, J., Jin, Z., Zhang, H., Tian, M., & Chen, H. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119678 · Cited by 60
Tau-Targeted Multifunctional Nanoinhibitor for Alzheimer’s Disease
Zhu, L., Xu, L., Wu, X., Deng, F., Ma, R., Liu, Y., Huang, F., & Shi, L. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c00257 · Cited by 57
Wang, G., Berry, S., Xiong, C., Hassenstab, J., Quintana, M., McDade, E. M., Delmar, P., Vestrucci, M., Sethuraman, G., Bateman, R. J., et al. (2018) · Statistics in Medicine · doi:10.1002/sim.7811 · Cited by 58
“Overall, these shortcomings have resulted in trial designs that require large sample sizes and long exposure to achieve acceptable statistical power.(2,6,7) We demonstrate that a disease progression model (DPM) built from the Dominantly Inherited Alzheimer Network (DIAN) observational cohort avoids each of these short…”
BackgroundEspay, A. J., & Lang, A. E. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181465 · Cited by 61
Broadstock, M., Ballard, C., & Corbett, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.936848 · Cited by 58
Moonga, I., Niccolini, F., Wilson, H., Pagano, G., Politis, M., & Initiative, T. A. D. N. (2017) · European Journal of Neurology · doi:10.1111/ene.13374 · Cited by 61
Martínková, J., Quevenco, F., Karcher, H., Ferrari, A., Sandset, E. C., Szoeke, C. E. I., Hort, J., Schmidt, R., Chadha, A. S., & Ferretti, M. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24124 · Cited by 68
Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials
Tian Hui Kwan, A., Arfaie, S., Therriault, J., Rosa-Neto, P., & Gauthier, S. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000511506 · Cited by 57
Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management
Galvin, J. E., Aisen, P., Langbaum, J. B., Rodriguez, E., Sabbagh, M., Stefanacci, R., Stern, R. A., Vassey, E. A., de Wilde, A., West, N., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.592302 · Cited by 56
“The implementation of this paradigm may not only improve current patient care, but also prepare our healthcare system for the anticipated increasing number of patients with AD who seek care following the approval of one or more investigational therapies targeting the underlying pathophysiology of AD (20, 21).”
BackgroundSelf-citationAlzheimer disease neuropathology in a patient previously treated with aducanumab
Plowey, E. D., Bussiere, T., Rajagovindan, R., Sebalusky, J., Hamann, S., von Hehn, C., Castrillo-Viguera, C., Sandrock, A., Budd Haeberlein, S., van Dyck, C. H., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02433-4 · Cited by 56
“Unlike aducanumab, solanezumab binds to soluble monomeric—not fibrillar deposited—Aβ and has been reported to have no significant impact on 18F-florbetapir PET SUVR in patients with baseline and Week 80 follow-up studies [8].”
BackgroundPhysiological Roles of Monomeric Amyloid-β and Implications for Alzheimer’s Disease Therapeutics
Jeong, H., Shin, H., Hong, S., & Kim, Y. S. (2022) · Experimental Neurobiology · doi:10.5607/en22004 · Cited by 65
Lessons Learned from Approval of Aducanumab for Alzheimer's Disease
Heidebrink, J. L., & Paulson, H. L. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-051022-043645 · Cited by 70
Söderberg, L., Johannesson, M., Gkanatsiou, E., Nygren, P., Fritz, N., Zachrisson, O., Rachalski, A., Svensson, A.-S., Button, E. B., Dentoni, G., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61691-2 · Cited by 71
Amyloid-β-targeting immunotherapies for Alzheimer's disease
Jin, Y., Du, Q., Song, M., Kang, R., Zhou, J., Zhang, H., & Ding, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.012 · Cited by 65
Protein aggregation, misfolding and consequential human neurodegenerative diseases
Sami, N., Rahman, S., Kumar, V., Zaidi, S., Islam, A., Ali, S., Ahmad, F., & Hassan, M. I. (2017) · International Journal of Neuroscience · doi:10.1080/00207454.2017.1286339 · Cited by 64
The companion dog as a unique translational model for aging
Mazzatenta, A., Carluccio, A., Robbe, D., Giulio, C. D., & Cellerino, A. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.08.024 · Cited by 60
Randomized, controlled, proof‐of‐concept trial of MK‐7622 in Alzheimer's disease
Voss, T., Li, J., Cummings, J., Farlow, M., Assaid, C., Froman, S., Leibensperger, H., Snow‐Adami, L., McMahon, K. B., Egan, M., et al. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.004 · Cited by 56
Self-citationPassive antiamyloid immunotherapy for Alzheimer's disease
Loureiro, J. C., Pais, M. V., Stella, F., Radanovic, M., Teixeira, A. L., Forlenza, O. V., & de Souza, L. C. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000587 · Cited by 56
“Both studies failed to show improvements in cognition or functional abilities after 80 weeks of treatment [14].”
Zhang, C., Kuo, C., Moghadam, S. H., Monte, L., Campbell, S. N., Rice, K. C., Sawchenko, P. E., Masliah, E., & Rissman, R. A. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.09.007 · Cited by 60
Cross-species translation of the Morris maze for Alzheimer’s disease
Possin, K. L., Sanchez, P. E., Anderson-Bergman, C., Fernandez, R., Kerchner, G. A., Johnson, E. T., Davis, A., Lo, I., Bott, N. T., Kiely, T., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci78464 · Cited by 56
Posner, H. B., Curiel, R. E., Edgar, C. J., Hendrix, S. B., Liu, E., Loewenstein, D., Morrison, G., Shinobu, L. A., Wesnes, K. A., & Harvey, P. D. (2017) · PubMed Central · Cited by 68
Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer’s Disease
Mantile, F., & Prisco, A. (2020) · Biology · doi:10.3390/biology9120425 · Cited by 56
“Solanezumab, a humanized IgG1 analog of a murine antibody that targets the central domain of Aβ and is selective for soluble forms, failed to improve cognition or functional ability in patients with mild-to-moderate Alzheimer’s disease [89], and in patients with mild dementia due to Alzheimer’s disease [41], and did n…”
BackgroundThe Failure of Solanezumab — How the FDA Saved Taxpayers Billions
Sacks, C. A., Avorn, J., & Kesselheim, A. S. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1701047 · Cited by 55
Structural and Functional Hippocampal Changes in Subjective Cognitive Decline From the Community
Liang, L., Zhao, L., Wei, Y., Mai, W., Duan, G., Su, J., Nong, X., Yu, B., Li, C., Mo, X., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00064 · Cited by 63
“However, there are no effective treatments for AD, and recent drugs targeting tau pathology and amyloid-β at the mild or moderate dementia stage have failed to treat the disease (Doody et al., 2014; Salloway et al., 2014).”
BackgroundMetabolic disorder in Alzheimer’s disease
Poddar, M. K., Banerjee, S., Chakraborty, A., & Dutta, D. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00673-z · Cited by 62
Recent advancement in therapeutic strategies for Alzheimer’s disease: Insights from clinical trials
Khan, T., Waseem, R., Shahid, M., Ansari, J., Ahanger, I. A., Hassan, M. I., & Islam, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102113 · Cited by 62
Vallés, A. S., Borroni, M. V., & Barrantes, F. J. (2014) · CNS Drugs · doi:10.1007/s40263-014-0201-3 · Cited by 66
Dekker, A. D., Sacco, S., Carfì, A., Benejam, B., Vermeiren, Y., Beugelsdijk, G., Schippers, M., Hassefras, L., Eleveld, J., Grefelman, S., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170920 · Cited by 65
RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORK
Cummings, J., Aisen, P., Barton, R., Bork, J., Doody, R., Dwyer, J., Egan, J. C., Feldman, H., Lappin, D., Truyen, L., et al. (2016) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2016.93 · Cited by 55
Self-citationTDP-43: From Alzheimer’s Disease to Limbic-Predominant Age-Related TDP-43 Encephalopathy
Huang, W., Zhou, Y., Tu, L., Ba, Z., Huang, J., Huang, N., & Luo, Y. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00026 · Cited by 60
Targeting MicroRNA-485-3p Blocks Alzheimer’s Disease Progression
Koh, H., Lee, S., Lee, H., Min, J.-W., Iwatsubo, T., Teunissen, C., Cho, H.-J., & Ryu, J.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313136 · Cited by 53
Self-citationInsights into the use of biomarkers in clinical trials in Alzheimer's disease
Pascoal, T. A., Aguzzoli, C. S., Lussier, F. Z., Crivelli, L., Suemoto, C. K., Fortea, J., Rosa‐Neto, P., Zimmer, E. R., Ferreira, P. C. L., & Bellaver, B. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105322 · Cited by 68
“19,21,87,91 Solanezumab did not decrease but increased CSF NfL neurodegeneration and did not affect microglial (TREM2) or astrocytic (GFAP) biomarkers.”
Phantom criteria for qualification of brain FDG and amyloid PET across different cameras
Ikari, Y., Akamatsu, G., Nishio, T., Ishii, K., Ito, K., Iwatsubo, T., & Senda, M. (2016) · EJNMMI Physics · doi:10.1186/s40658-016-0159-y · Cited by 59
Self-citationPoon, A., Zhang, Y., Chandrasekaran, A., Phanthong, P., Schmid, B., Nielsen, T. T., & Freude, K. K. (2017) · New Biotechnology · doi:10.1016/j.nbt.2017.05.009 · Cited by 46
Machine Learning Predictive Models Can Improve Efficacy of Clinical Trials for Alzheimer’s Disease
Ezzati, A., Initiative, A. D. N., & Lipton, R. B. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190822 · Cited by 60
“More recently these criteria became stricter and in addition to previous criteria, patients need to meet certain biomarker-based criteria such as amyloid positivity on positron emission tomography (PET) scans or have evidence of neurodegeneration (e.g., hippocampal atrophy) to pass the screening…”
Aging-Dependent Mitophagy Dysfunction in Alzheimer’s Disease
Song, M., Zhao, X., & Song, F. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02248-y · Cited by 60
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecìć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 56
“Two phase 3 studies (EXPEDITION and EXPEDITION2) did not achieve statistical significance on the primary outcome, but a small trend for slowing of progression was evident, with most secondary outcomes achieving nominal statistical significance (Doody et al., 2014).”
BackgroundSelf-citationThe Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes
Kepp, K. P., Sensi, S. L., Johnsen, K. B., Barrio, J. R., Høilund-Carlsen, P. F., Neve, R. L., Alavi, A., Herrup, K., Perry, G., Robakis, N. K., et al. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-230099 · Cited by 53
Mably, A. J., Liu, W., Mc Donald, J. M., Dodart, J.-C., Bard, F., Lemere, C. A., O'Nuallain, B., & Walsh, D. M. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.07.008 · Cited by 53
Systems biology of neurodegenerative diseases
Wood, L. B., Winslow, A. R., & Strasser, S. D. (2015) · Integrative Biology · doi:10.1039/c5ib00031a · Cited by 53
Shao, H., Zhang, Y., Dong, Y., Yu, B., Xia, W., & Xie, Z. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132792 · Cited by 53
Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease
Panza, F., Solfrizzi, V., Imbimbo, B. P., Giannini, M., Santamato, A., Seripa, D., & Logroscino, G. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.945522 · Cited by 53
Alzheimer's disease: Only prevention makes sense
Viña, J., & Sanz‐Ros, J. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13005 · Cited by 57
“However, no effect on amyloid accumulation was evident using florbetapir (PIB) as a tracer for PET.(3) A similar approach was tested using bapineuzumab.”
MethodInfluentialCho, H., Sharma, A. K., Zhang, Y., Gross, M. L., & Mirica, L. M. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00114 · Cited by 59
Quantum Dots as A Theranostic Approach in Alzheimer’s Disease: A Systematic Review
Villalva, M. D., Agarwal, V., Ulanova, M., Sachdev, P. S., & Braidy, N. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0104 · Cited by 53
Amyloid-Beta Solubility in the Treatment of Alzheimer’s Disease
Murphy, M. P. (2018) · New England Journal of Medicine · doi:10.1056/nejme1714638 · Cited by 53
Feinberg, H., Saldanha, J. W., Diep, L., Goel, A., Widom, A., Veldman, G. M., Weis, W. I., Schenk, D., & Basi, G. S. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt261 · Cited by 52
Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly
Westwood, S., Leoni, E., Hye, A., Lynham, S., Khondoker, M. R., Ashton, N. J., Kiddle, S. J., Baird, A. L., Sáinz‐Fuertes, R., Leung, R., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151155 · Cited by 53
Buechler, J., & Salinas, P. C. (2018) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2018.00038 · Cited by 51
The Interaction Between NF-κB and Estrogen in Alzheimer’s Disease
Mishra, P., Davies, D. A., & Albensi, B. C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-022-03152-3 · Cited by 51
“However, in the past, efforts to use agents like solanezumab and bapineuzumab to decrease Aβ levels in patients with AD have failed to show benefits in clinical trials [14, 15].”
BackgroundAranda, M., Márquez, D. X., Gallagher-Thompson, D. E., Pérez, A., Rojas, J. C., Hill, C. V., Reyes, Y., Dilworth‐Anderson, P., & Portacolone, E. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12389 · Cited by 63
Passive Alzheimer’s immunotherapy: A promising or uncertain option?
Høilund‐Carlsen, P. F., Revheim, M.-E. R., Costa, T., Alavi, A. A., Kepp, K. P., Sensi, S. L., Perry, G. L., Robakis, N. K. R. K., Barrio, J. R., & Vissel, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101996 · Cited by 56
Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology
Voyle, N., Baker, D., Burnham, S. C., Covin, A., Zhang, Z., Sangurdekar, D. P., Tan Hehir, C. A., Bazenet, C., Lovestone, S., Kiddle, S., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150020 · Cited by 50
Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged
Rothstein, T. L. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00127 · Cited by 56
Ma, J., Gao, Y., Jiang, L., Chao, F.-L., Huang, W., Zhou, C.-N., Tang, W., Zhang, L., Huang, C.-X., Zhang, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15398 · Cited by 51
“Whether reducing beta amyloid is beneficial to the pathogenesis of AD remains controversial, given that several lines of evidence have revealed that drugs targeting to clear the beta amyloid protein plaques fail to improve cognition in AD patients and may even result in terrible side effects, such as skin cancer [69,…”
BackgroundYou, J. C., Jones, E., Cross, D. E., Lyon, A. C., Kang, H., Newberg, A. B., & Lippa, C. F. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.13383 · Cited by 49
Antibody Therapeutics Targeting Aβ and Tau
Gallardo, G., & Holtzman, D. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024331 · Cited by 50
“Aducanumab” making a comeback in Alzheimer’s disease: An old wine in a new bottle
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Makeen, H. A., Albratty, M., Alhazmi, H. A., Felemban, S. G., Alsubayiel, A. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112746 · Cited by 50
Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies
Bittar, A., Sengupta, U., & Kayed, R. (2018) · npj Vaccines · doi:10.1038/s41541-018-0046-8 · Cited by 50
“However, Phase 3 trials did not show any clinical efficacy either and thus solanezumab was also abandoned until last year (ID: NCT00905372 and NCT00904683).(128) Solanezumab is back in clinical trials (ID NCT02008357, clinicaltrials.”
Background
Metadata
- Authors
- Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Centre Hospitalier Universitaire de Toulouse (FR)
- University of Pennsylvania (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 311-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015484447
- Cited by
- 1,668
- References
- 28
- Citations by year
- 2026: 63 · 2025: 84 · 2024: 110 · 2023: 116 · 2022: 101 · 2021: 103 · 2020: 154 · 2019: 145 · 2018: 155 · 2017: 163 · 2016: 183 · 2015: 178 · 2014: 111
- FWCI
- 140.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, cognitive impairment, activities of daily living, mild to moderate Alzheimer's disease, placebo response
- MeSH terms
- Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Cognition, Double-Blind Method, Female, Humans, Male, Neuropsychological Tests, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.